Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$294K Buy
47,727
+20,566
+76% +$171K ﹤0.01% 2899
2025
Q4
$284K Sell
27,161
-3,883
-13% -$39K ﹤0.01% 2895
2025
Q3
$279K Buy
31,044
+19,180
+162% +$168K ﹤0.01% 2876
2025
Q2
$154K Buy
+11,864
New +$178K ﹤0.01% 3134
2025
Q1
Sell
-12,080
Closed -$415K 3558
2024
Q4
$415K Sell
12,080
-274
-2% -$12.4K ﹤0.01% 2338
2024
Q3
$611K Sell
12,354
-2,194
-15% -$112K ﹤0.01% 1972
2024
Q2
$875K Buy
14,548
+1,865
+15% +$107K ﹤0.01% 1604
2024
Q1
$654K Buy
12,683
+1,315
+12% +$64.5K ﹤0.01% 1831
2023
Q4
$458K Sell
11,368
-822
-7% -$24.1K ﹤0.01% 1995
2023
Q3
$340K Buy
12,190
+1,232
+11% +$36.7K ﹤0.01% 2047
2023
Q2
$317K Buy
10,958
+857
+8% +$19.1K ﹤0.01% 2077
2023
Q1
$168K Buy
+10,101
New +$143K ﹤0.01% 2459

Other funds holding RXST

Mariner's RXST Position: Q1 2026 in Review

Mariner increased its RxSight (RXST) stake by 76% in Q1 2026, buying an estimated $171K and bringing the position to 47,727 shares worth $294K. The position accounts for ﹤0.01% of the portfolio, ranked #2899.

Mariner first reported a position in RXST in Q1 2023 and has held it in 12 quarters since. The position peaked at $875K in Q2 2024. 164 funds tracked by Wall St. Rank hold RXST as of Q1 2026.

  • Mariner held 47,727 shares of RxSight worth $294K as of Q1 2026.
  • Mariner bought 20,566 RxSight shares in Q1 2026, an estimated $171K.
  • RxSight made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #2899 holding.
  • Mariner first reported a position in RxSight in Q1 2023 and has held it in 12 quarters since.
  • Mariner's RxSight position peaked at $875K in Q2 2024.
  • 164 funds tracked by Wall St. Rank held RxSight as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.